The prostate cancer devices market is growing due to increase in aging population and increase in research and development in oncology therapeutic area. Limited players in the market and increasing pharmaceutical expenditure by emerging markets are some of the factors providing ample opportunities to the prostate cancer devices market to grow at a considerable rate in the coming years. Adoption of robotic prostatectomy is one of the major trends seen in the prostate cancer devices market.

Some of the ways to diagnose prostate cancer are prostate biopsy, digital rectal exam, pet and spect scans, ultrasound, prostascint monoclonal antibody scan, prostate-specific antigen blood test, lymph node biopsy, CT scan, MRI, and bone scan. The causes by which the prostate cancer occurs are, diet or lifestyle factors, age, infection or inflammation of the prostate gland, family history or genetics, obesity, and race. Stages of prostate cancer are categorized as stage I, stage II, stage III and stage IV.

On the basis of products, the prostate cancer devices market can be categorized as chemotherapy, hormonal therapy and immunotherapy. Chemotherapy consists of mitoxantrone, taxotere, estramustine and jevtana. Hormonal therapy consists of luteinizing hormone-releasing hormone antagonists, anti-androgens and luteinizing hormone-releasing hormone analogs. Luteinizing hormone-releasing hormone analogs include decapeptyl, lupron, vantas, zoladex and eligard.

The prostate cancer devices market can be categorized on the basis of applications as external beam radiation therapy, radical prostatectomy, cryotherapy, high intensity focused ultrasound (HIFU), robotic surgery, brachytherapy and laparoscopic surgery. Brachytherapy, also known as internal radiotherapy, is an emerging early stage treatment option for prostate cancer. In the treatment, radioactive sources or seeds are placed near the tumor to give out a high radiation dose to the tumor. Simultaneously, the radioactive seeds decrease the radiation contact in the surrounding healthy tissues.

Some of the competitors in the prostate cancer devices market are Varian Medical Systems, Inc., Galil Medical Inc., Intuitive Surgical, Inc., Elekta AB, Eckert & Ziegler BEBIG, Siemens Healthcare, and Philips Healthcare.